Supporting this, numerous studies have reported a lower specificity or higher false positive rate in GEC tests among indeterminate nodules with HC predominance. Brauner et al. reported 86% (37/43) patients with a GEC suspicious result had unnecessary surgery (46). The authors include a grouped cohort analysis of 122 HC predominant nodules between 2012 and 2014, showing 85 of 95 (89.5%) benign pathologies identified as GEC suspicious (46). Another study by Parajuli et al. reported on GEC’s increase in false positive rate among HC predominant nodules, but did not observe the same increase in Thyroseq® V2 (66). Additional studies assessing Thyroseq®’s performance in HC predominant nodules are lacking.